Microbial metabolites in non-alcoholic fatty liver disease
|
摘要
The prevalence of non-alcoholic fatty liver disease(NAFLD) is rising exponentially worldwide. The spectrum of NAFLD includes non-alcoholic fatty liver, non-alcoholic steatohepatitis, liver cirrhosis, and even hepatocellular carcinoma. Evidence shows that microbial metabolites play pivotal roles in the onset and progression of NAFLD. In this review, we discuss how microbederived metabolites, such as short-chain fatty acids, endogenous ethanol, bile acids and so forth, contribute to the pathogenesis of NAFLD.
The prevalence of non-alcoholic fatty liver disease(NAFLD) is rising exponentially worldwide. The spectrum of NAFLD includes non-alcoholic fatty liver, non-alcoholic steatohepatitis, liver cirrhosis, and even hepatocellular carcinoma. Evidence shows that microbial metabolites play pivotal roles in the onset and progression of NAFLD. In this review, we discuss how microbederived metabolites, such as short-chain fatty acids, endogenous ethanol, bile acids and so forth, contribute to the pathogenesis of NAFLD.
The prevalence of non-alcoholic fatty liver disease(NAFLD) is rising exponentially worldwide. The spectrum of NAFLD includes non-alcoholic fatty liver, non-alcoholic steatohepatitis, liver cirrhosis, and even hepatocellular carcinoma. Evidence shows that microbial metabolites play pivotal roles in the onset and progression of NAFLD. In this review, we discuss how microbederived metabolites, such as short-chain fatty acids, endogenous ethanol, bile acids and so forth, contribute to the pathogenesis of NAFLD.
引文
1 Wang FS,Fan JG,Zhang Z,Gao B,Wang HY.The global burden of liver disease:the major impact of China.Hepatology 2014;60:2099-2108[PMID:25164003 DOI:10.1002/hep.27406]
2 Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLD in Asia.J Hepatol 2017;67:862-873[PMID:28642059 DOI:10.1016/j.jhep.2017.06.003]
3 Day CP,James OF.Steatohepatitis:a tale of two"hits"?Gastroenterology 1998;114:842-845[PMID:9547102]
4 Tilg H,Moschen AR.Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis.Hepatology 2010;52:1836-1846[PMID:21038418 DOI:10.1002/hep.24001]
5 Diehl AM,Day C.Cause,Pathogenesis,and Treatment of Nonalcoholic Steatohepatitis.N Engl J Med2017;377:2063-2072[PMID:29166236 DOI:10.1056/NEJMra1503519]
6 Le Roy T,Llopis M,Lepage P,Bruneau A,Rabot S,Bevilacqua C,Martin P,Philippe C,Walker F,Bado A,Perlemuter G,Cassard-Doulcier AM,Gérard P.Intestinal microbiota determines development of nonalcoholic fatty liver disease in mice.Gut 2013;62:1787-1794[PMID:23197411 DOI:10.1136/gutjnl-2012-303816]
7 Khan R,Bril F,Cusi K,Newsome PN.Modulation of Insulin Resistance in NAFLD.Hepatology 2018[PMID:30556145 DOI:10.1002/hep.30429]
8 Blaut M.Gut microbiota and energy balance:role in obesity.Proc Nutr Soc 2015;74:227-234[PMID:25518735 DOI:10.1017/S0029665114001700]
9 Shen F,Zheng RD,Sun XQ,Ding WJ,Wang XY,Fan JG.Gut microbiota dysbiosis in patients with nonalcoholic fatty liver disease.Hepatobiliary Pancreat Dis Int 2017;16:375-381[PMID:28823367 DOI:10.1016/S1499-3872(17)60019-5]
10 Cao Y,Pan Q,Cai W,Shen F,Chen GY,Xu LM,Fan JG.Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.Arch Iran Med 2016;19:197-203[PMID:26923892 DOI:10.1002/hep.29892]
11 Chu H,Duan Y,Yang L,Schnabl B.Small metabolites,possible big changes:a microbiota-centered view of non-alcoholic fatty liver disease.Gut 2019;68:359-370[PMID:30171065 DOI:10.1136/gutjnl-2018-316307]
12 Caussy C,Hsu C,Lo MT,Liu A,Bettencourt R,Ajmera VH,Bassirian S,Hooker J,Sy E,Richards L,Schork N,Schnabl B,Brenner DA,Sirlin CB,Chen CH,Loomba R;Genetics of NAFLD in Twins Consortium.Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.Hepatology 2018[PMID:29572891 DOI:10.1002/hep.29892]
13 Del Chierico F,Nobili V,Vernocchi P,Russo A,Stefanis C,Gnani D,Furlanello C,ZandonàA,Paci P,Capuani G,Dallapiccola B,Miccheli A,Alisi A,Putignani L.Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.Hepatology 2017;65:451-464[PMID:27028797 DOI:10.1002/hep.28572]
14 Loomba R,Seguritan V,Li W,Long T,Klitgord N,Bhatt A,Dulai PS,Caussy C,Bettencourt R,Highlander SK,Jones MB,Sirlin CB,Schnabl B,Brinkac L,Schork N,Chen CH,Brenner DA,Biggs W,Yooseph S,Venter JC,Nelson KE.Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.Cell Metab 2017;25:1054-1062.e5[PMID:28467925 DOI:10.1016/j.cmet.2017.04.001]
15 Boursier J,Mueller O,Barret M,Machado M,Fizanne L,Araujo-Perez F,Guy CD,Seed PC,Rawls JF,David LA,Hunault G,Oberti F,Calès P,Diehl AM.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.Hepatology 2016;63:764-775[PMID:26600078 DOI:10.1002/hep.28356]
16 Hoyles L,Fernández-Real JM,Federici M,Serino M,Abbott J,Charpentier J,Heymes C,Luque JL,Anthony E,Barton RH,Chilloux J,Myridakis A,Martinez-Gili L,Moreno-Navarrete JM,Benhamed F,Azalbert V,Blasco-Baque V,Puig J,Xifra G,Ricart W,Tomlinson C,Woodbridge M,Cardellini M,Davato F,Cardolini I,Porzio O,Gentileschi P,Lopez F,Foufelle F,Butcher SA,Holmes E,Nicholson JK,Postic C,Burcelin R,Dumas ME.Molecular phenomics and metagenomics of hepatic steatosis in nondiabetic obese women.Nat Med 2018;24:1070-1080[PMID:29942096 DOI:10.1038/s41591-018-0061-3]
17 Panasevich MR,Peppler WT,Oerther DB,Wright DC,Rector RS.Microbiome and NAFLD:potential influence of aerobic fitness and lifestyle modification.Physiol Genomics 2017;49:385-399[PMID:28600319 DOI:10.1152/physiolgenomics.00012.2017]
18 Canfora EE,Meex RCR,Venema K,Blaak EE.Gut microbial metabolites in obesity,NAFLD and T2DM.Nat Rev Endocrinol 2019[PMID:30670819 DOI:10.1038/s41574-019-0156-z]
19 Chambers ES,Viardot A,Psichas A,Morrison DJ,Murphy KG,Zac-Varghese SE,MacDougall K,Preston T,Tedford C,Finlayson GS,Blundell JE,Bell JD,Thomas EL,Mt-Isa S,Ashby D,Gibson GR,Kolida S,Dhillo WS,Bloom SR,Morley W,Clegg S,Frost G.Effects of targeted delivery of propionate to the human colon on appetite regulation,body weight maintenance and adiposity in overweight adults.Gut2015;64:1744-1754[PMID:25500202 DOI:10.1136/gutjnl-2014-307913]
20 Schwiertz A,Taras D,Sch?fer K,Beijer S,Bos NA,Donus C,Hardt PD.Microbiota and SCFA in lean and overweight healthy subjects.Obesity(Silver Spring)2010;18:190-195[PMID:19498350 DOI:10.1038/oby.2009.167]
21 Zhou D,Pan Q,Liu XL,Yang RX,Chen YW,Liu C,Fan JG.Clostridium butyricum B1 alleviates highfat diet-induced steatohepatitis in mice via enterohepatic immunoregulation.J Gastroenterol Hepatol2017;32:1640-1648[PMID:28109017 DOI:10.1111/jgh.13742]
22 Liang Y,Lin C,Zhang Y,Deng Y,Liu C,Yang Q.Probiotic mixture of Lactobacillus and Bifidobacterium alleviates systemic adiposity and inflammation in non-alcoholic fatty liver disease rats through Gpr109a and the commensal metabolite butyrate.Inflammopharmacology 2018;26:1051-1055[PMID:29633106 DOI:10.1007/s10787-018-0479-8]
23 Zhou D,Pan Q,Shen F,Cao HX,Ding WJ,Chen YW,Fan JG.Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota.Sci Rep2017;7:1529[PMID:28484247 DOI:10.1038/s41598-017-01751-y]
24 Zhao L,Zhang F,Ding X,Wu G,Lam YY,Wang X,Fu H,Xue X,Lu C,Ma J,Yu L,Xu C,Ren Z,Xu Y,Xu S,Shen H,Zhu X,Shi Y,Shen Q,Dong W,Liu R,Ling Y,Zeng Y,Wang X,Zhang Q,Wang J,Wang L,Wu Y,Zeng B,Wei H,Zhang M,Peng Y,Zhang C.Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes.Science 2018;359:1151-1156[PMID:29590046 DOI:10.1126/science.aao5774]
25 Bjursell M,Admyre T,G?ransson M,Marley AE,Smith DM,Oscarsson J,Bohlooly-Y M.Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet.Am J Physiol Endocrinol Metab 2011;300:E211-E220[PMID:20959533 DOI:10.1152/ajpendo.00229.2010]
26 Samuel BS,Shaito A,Motoike T,Rey FE,Backhed F,Manchester JK,Hammer RE,Williams SC,Crowley J,Yanagisawa M,Gordon JI.Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor,Gpr41.Proc Natl Acad Sci USA 2008;105:16767-16772[PMID:18931303 DOI:10.1073/pnas.0808567105]
27 Kaji I,Karaki S,Kuwahara A.Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release.Digestion 2014;89:31-36[PMID:24458110 DOI:10.1159/000356211]
28 Schilderink R,Verseijden C,de Jonge WJ.Dietary inhibitors of histone deacetylases in intestinal immunity and homeostasis.Front Immunol 2013;4:226[PMID:23914191 DOI:10.3389/fimmu.2013.00226]
29 Zhou D,Pan Q,Xin FZ,Zhang RN,He CX,Chen GY,Liu C,Chen YW,Fan JG.Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.World J Gastroenterol 2017;23:60-75[PMID:28104981 DOI:10.3748/wjg.v23.i1.60]
30 Zhou D,Chen YW,Zhao ZH,Yang RX,Xin FZ,Liu XL,Pan Q,Zhou H,Fan JG.Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1Rexpression.Exp Mol Med 2018;50:157[PMID:30510243 DOI:10.1038/s12276-018-0183-1]
31 Singh V,Yeoh BS,Chassaing B,Xiao X,Saha P,Aguilera Olvera R,Lapek JD,Zhang L,Wang WB,Hao S,Flythe MD,Gonzalez DJ,Cani PD,Conejo-Garcia JR,Xiong N,Kennett MJ,Joe B,Patterson AD,Gewirtz AT,Vijay-Kumar M.Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer.Cell 2018;175:679-694.e22[PMID:30340040 DOI:10.1016/j.cell.2018.09.004]
32 Cani PD.Microbiota and metabolites in metabolic diseases.Nat Rev Endocrinol 2019;15:69-70[PMID:30602737 DOI:10.1038/s41574-018-0143-9]
33 Fuster D,Samet JH.Alcohol Use in Patients with Chronic Liver Disease.N Engl J Med 2018;379:1251-1261[PMID:30257164 DOI:10.1056/NEJMra1715733]
34 Cope K,Risby T,Diehl AM.Increased gastrointestinal ethanol production in obese mice:implications for fatty liver disease pathogenesis.Gastroenterology 2000;119:1340-1347[PMID:11054393 DOI:10.1053/gast.2000.19267]
35 Zhu L,Baker SS,Gill C,Liu W,Alkhouri R,Baker RD,Gill SR.Characterization of gut microbiomes in nonalcoholic steatohepatitis(NASH)patients:a connection between endogenous alcohol and NASH.Hepatology 2013;57:601-609[PMID:23055155 DOI:10.1002/hep.26093]
36 Michail S,Lin M,Frey MR,Fanter R,Paliy O,Hilbush B,Reo NV.Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease.FEMS Microbiol Ecol 2015;91:1-9[PMID:25764541 DOI:10.1093/femsec/fiu002]
37 Engstler AJ,Aumiller T,Degen C,Dürr M,Weiss E,Maier IB,Schattenberg JM,Jin CJ,Sellmann C,Bergheim I.Insulin resistance alters hepatic ethanol metabolism:studies in mice and children with nonalcoholic fatty liver disease.Gut 2016;65:1564-1571[PMID:26006114 DOI:10.1136/gutjnl-2014-308379]
38 Dornas W,Lagente V.Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis.Pharmacol Res 2019;141:418-428[PMID:30658094 DOI:10.1016/j.phrs.2019.01.026]
39 Sharifnia T,Antoun J,Verriere TG,Suarez G,Wattacheril J,Wilson KT,Peek RM,Abumrad NN,Flynn CR.Hepatic TLR4 signaling in obese NAFLD.Am J Physiol Gastrointest Liver Physiol 2015;309:G270-G278[PMID:26113297 DOI:10.1152/ajpgi.00304.2014]
40 Duparc T,Plovier H,Marrachelli VG,Van Hul M,Essaghir A,St?hlman M,Matamoros S,Geurts L,Pardo-Tendero MM,Druart C,Delzenne NM,Demoulin JB,van der Merwe SW,van Pelt J,B?ckhed F,Monleon D,Everard A,Cani PD.Hepatocyte MyD88 affects bile acids,gut microbiota and metabolome contributing to regulate glucose and lipid metabolism.Gut 2017;66:620-632[PMID:27196572 DOI:10.1136/gutjnl-2015-310904]
41 Kawaratani H,Tsujimoto T,Kitazawa T,Kitade M,Yoshiji H,Uemura M,Fukui H.Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet.World J Gastroenterol2008;14:6655-6661[PMID:19034968 DOI:10.3748/wjg.14.6655]
42 Diether NE,Willing BP.Microbial Fermentation of Dietary Protein:An Important Factor in DietMicrobeHost Interaction.Microorganisms 2019;7[PMID:30642098 DOI:10.3390/microorganisms7010019]
43 Goffredo M,Santoro N,TricòD,Giannini C,D'Adamo E,Zhao H,Peng G,Yu X,Lam TT,Pierpont B,Caprio S,Herzog RI.A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease.Nutrients 2017;9[PMID:28640216 DOI:10.3390/nu9070642]
44 Kaikkonen JE,Würtz P,Suomela E,Lehtovirta M,Kangas AJ,Jula A,Mikkil?V,Viikari JS,Juonala M,R?nnemaa T,Hutri-K?h?nen N,K?h?nen M,Lehtim?ki T,Soininen P,Ala-Korpela M,Raitakari OT.Metabolic profiling of fatty liver in young and middle-aged adults:Cross-sectional and prospective analyses of the Young Finns Study.Hepatology 2017;65:491-500[PMID:27775848 DOI:10.1002/hep.28899]
45 Ottosson F,Brunkwall L,Ericson U,Nilsson PM,Almgren P,Fernandez C,Melander O,Orho-Melander M.Connection Between BMI-Related Plasma Metabolite Profile and Gut Microbiota.J Clin Endocrinol Metab 2018;103:1491-1501[PMID:29409054 DOI:10.1210/jc.2017-02114]
46 Zhang F,Zhao S,Yan W,Xia Y,Chen X,Wang W,Zhang J,Gao C,Peng C,Yan F,Zhao H,Lian K,Lee Y,Zhang L,Lau WB,Ma X,Tao L.Branched Chain Amino Acids Cause Liver Injury in Obese/Diabetic Mice by Promoting Adipocyte Lipolysis and Inhibiting Hepatic Autophagy.EBioMedicine 2016;13:157-167[PMID:27843095 DOI:10.1016/j.ebiom.2016.10.013]
47 Li T,Geng L,Chen X,Miskowiec M,Li X,Dong B.Branched-chain amino acids alleviate nonalcoholic steatohepatitis in rats.Appl Physiol Nutr Metab 2013;38:836-843[PMID:23855271 DOI:10.1139/apnm-2012-0496]
48 Tanaka H,Fukahori S,Baba S,Ueno T,Sivakumar R,Yagi M,Asagiri K,Ishii S,Tanaka Y.BranchedChain Amino Acid-Rich Supplements Containing Microelements Have Antioxidant Effects on Nonalcoholic Steatohepatitis in Mice.JPEN J Parenter Enteral Nutr 2016;40:519-528[PMID:25316683DOI:10.1177/0148607114555160]
49 Honda T,Ishigami M,Luo F,Lingyun M,Ishizu Y,Kuzuya T,Hayashi K,Nakano I,Ishikawa T,Feng GG,Katano Y,Kohama T,Kitaura Y,Shimomura Y,Goto H,Hirooka Y.Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice.Metabolism 2017;69:177-187[PMID:28285648 DOI:10.1016/j.metabol.2016.12.013]
50 Anzai A,Marcondes RR,Gon?alves TH,Carvalho KC,Sim?es MJ,Soares JM Jr,Padmanabhan V,Baracat EC,da Silva IDCG,Maciel GAR.Impaired branched-chain amino acid metabolism may underlie the nonalcoholic fatty liver disease-like pathology of neonatal testosterone-treated female rats.Sci Rep2017;7:13167[PMID:29030588 DOI:10.1038/s41598-017-13451-8]
51 Zhou H,Yu B,Gao J,Htoo JK,Chen D.Regulation of intestinal health by branched-chain amino acids.Anim Sci J 2018;89:3-11[PMID:29164733 DOI:10.1111/asj.12937]
52 Fan JG;Shanghai Multicenter Clinical Cooperative Group of Danning Pian Trial.Evaluating the efficacy and safety of Danning Pian in the short-term treatment of patients with non-alcoholic fatty liver disease:a multicenter clinical trial.Hepatobiliary Pancreat Dis Int 2004;3:375-380[PMID:15313672]
53 Ferslew BC,Xie G,Johnston CK,Su M,Stewart PW,Jia W,Brouwer AS 4th.Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.Dig Dis Sci 2015;60:3318-3328[PMID:26138654 DOI:10.1007/s10620-015-3776-8]
54 Puri P,Daita K,Joyce A,Mirshahi F,Santhekadur PK,Cazanave S,Luketic VA,Siddiqui MS,Boyett S,Min HK,Kumar DP,Kohli R,Zhou H,Hylemon PB,Contos MJ,Idowu M,Sanyal AJ.The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.Hepatology 2017[PMID:28696585 DOI:10.1002/hep.29359]
55 Khandekar MJ,Cohen P,Spiegelman BM.Molecular mechanisms of cancer development in obesity.Nat Rev Cancer 2011;11:886-895[PMID:22113164 DOI:10.1038/nrc3174]
56 Yoshimoto S,Loo TM,Atarashi K,Kanda H,Sato S,Oyadomari S,Iwakura Y,Oshima K,Morita H,Hattori M,Honda K,Ishikawa Y,Hara E,Ohtani N.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.Nature 2013;499:97-101[PMID:23803760 DOI:10.1038/nature12347]
57 Jiao N,Baker SS,Chapa-Rodriguez A,Liu W,Nugent CA,Tsompana M,Mastrandrea L,Buck MJ,Baker RD,Genco RJ,Zhu R,Zhu L.Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.Gut 2018;67:1881-1891[PMID:28774887 DOI:10.1136/gutjnl-2017-314307]
58 Fan JG,Zhong L,Tia LY,Xu ZJ,Li MS,Wang GL.Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.World J Gastroenterol 2005;11:2346-2350[PMID:15818751 DOI:10.3748/wjg.v11.i15.2346]
59 Neuschwander-Tetri BA,Loomba R,Sanyal AJ,Lavine JE,Van Natta ML,Abdelmalek MF,Chalasani N,Dasarathy S,Diehl AM,Hameed B,Kowdley KV,McCullough A,Terrault N,Clark JM,Tonascia J,Brunt EM,Kleiner DE,Doo E;NASH Clinical Research Network.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):a multicentre,randomised,placebo-controlled trial.Lancet 2015;385:956-965[PMID:25468160 DOI:10.1016/S0140-6736(14)61933-4]
60 Arab JP,Karpen SJ,Dawson PA,Arrese M,Trauner M.Bile acids and nonalcoholic fatty liver disease:Molecular insights and therapeutic perspectives.Hepatology 2017;65:350-362[PMID:27358174 DOI:10.1002/hep.28709]
61 Ding L,Sousa KM,Jin L,Dong B,Kim BW,Ramirez R,Xiao Z,Gu Y,Yang Q,Wang J,Yu D,Pigazzi A,Schones D,Yang L,Moore D,Wang Z,Huang W.Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss,improve fatty liver,and remit insulin resistance in mice.Hepatology 2016;64:760-773[PMID:27312543 DOI:10.1002/hep.28689]
62 Guo C,Xie S,Chi Z,Zhang J,Liu Y,Zhang L,Zheng M,Zhang X,Xia D,Ke Y,Lu L,Wang D.Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome.Immunity 2016;45:802-816[PMID:27692610 DOI:10.1016/j.immuni.2016.09.008]
63 Nagahashi M,Takabe K,Liu R,Peng K,Wang X,Wang Y,Hait NC,Wang X,Allegood JC,Yamada A,Aoyagi T,Liang J,Pandak WM,Spiegel S,Hylemon PB,Zhou H.Conjugated bile acid-activated S1Preceptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression.Hepatology 2015;61:1216-1226[PMID:25363242 DOI:10.1002/hep.27592]
64 Smallwood T,Allayee H,Bennett BJ.Choline metabolites:gene by diet interactions.Curr Opin Lipidol2016;27:33-39[PMID:26655287 DOI:10.1097/MOL.0000000000000259]
65 Friedman SL,Neuschwander-Tetri BA,Rinella M,Sanyal AJ.Mechanisms of NAFLD development and therapeutic strategies.Nat Med 2018;24:908-922[PMID:29967350 DOI:10.1038/s41591-018-0104-9]
66 Wang Z,Klipfell E,Bennett BJ,Koeth R,Levison BS,Dugar B,Feldstein AE,Britt EB,Fu X,Chung YM,Wu Y,Schauer P,Smith JD,Allayee H,Tang WH,DiDonato JA,Lusis AJ,Hazen SL.Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.Nature 2011;472:57-63[PMID:21475195 DOI:10.1038/nature09922]
67 Wang Z,Roberts AB,Buffa JA,Levison BS,Zhu W,Org E,Gu X,Huang Y,Zamanian-Daryoush M,Culley MK,DiDonato AJ,Fu X,Hazen JE,Krajcik D,DiDonato JA,Lusis AJ,Hazen SL.Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis.Cell 2015;163:1585-1595[PMID:26687352 DOI:10.1016/j.cell.2015.11.055]
68 Bennett BJ,de Aguiar Vallim TQ,Wang Z,Shih DM,Meng Y,Gregory J,Allayee H,Lee R,Graham M,Crooke R,Edwards PA,Hazen SL,Lusis AJ.Trimethylamine-N-oxide,a metabolite associated with atherosclerosis,exhibits complex genetic and dietary regulation.Cell Metab 2013;17:49-60[PMID:23312283 DOI:10.1016/j.cmet.2012.12.011]
69 Chen YM,Liu Y,Zhou RF,Chen XL,Wang C,Tan XY,Wang LJ,Zheng RD,Zhang HW,Ling WH,Zhu HL.Associations of gut-flora-dependent metabolite trimethylamine-N-oxide,betaine and choline with non-alcoholic fatty liver disease in adults.Sci Rep 2016;6:19076[PMID:26743949 DOI:10.1038/srep19076]
70 Barrea L,Annunziata G,Muscogiuri G,Di Somma C,Laudisio D,Maisto M,de Alteriis G,Tenore GC,Colao A,Savastano S.Trimethylamine-N-oxide(TMAO)as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome.Nutrients 2018;10[PMID:30551613 DOI:10.3390/nu10121971]
71 Dumas ME,Barton RH,Toye A,Cloarec O,Blancher C,Rothwell A,Fearnside J,Tatoud R,Blanc V,Lindon JC,Mitchell SC,Holmes E,McCarthy MI,Scott J,Gauguier D,Nicholson JK.Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.Proc Natl Acad Sci USA 2006;103:12511-12516[PMID:16895997 DOI:10.1073/pnas.0601056103]
72 Gao X,Liu X,Xu J,Xue C,Xue Y,Wang Y.Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet.J Biosci Bioeng 2014;118:476-481[PMID:24721123 DOI:10.1016/j.jbiosc.2014.03.001]
73 Schugar RC,Shih DM,Warrier M,Helsley RN,Burrows A,Ferguson D,Brown AL,Gromovsky AD,Heine M,Chatterjee A,Li L,Li XS,Wang Z,Willard B,Meng Y,Kim H,Che N,Pan C,Lee RG,Crooke RM,Graham MJ,Morton RE,Langefeld CD,Das SK,Rudel LL,Zein N,McCullough AJ,Dasarathy S,Tang WHW,Erokwu BO,Flask CA,Laakso M,Civelek M,Naga Prasad SV,Heeren J,Lusis AJ,Hazen SL,Brown JM.The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue.Cell Rep 2017;19:2451-2461[PMID:28636934 DOI:10.1016/j.celrep.2017.05.077]
74 Dumas ME,Rothwell AR,Hoyles L,Aranias T,Chilloux J,Calderari S,Noll EM,Péan N,BoulangéCL,Blancher C,Barton RH,Gu Q,Fearnside JF,Deshayes C,Hue C,Scott J,Nicholson JK,Gauguier D.Microbial-Host Co-metabolites Are Prodromal Markers Predicting Phenotypic Heterogeneity in Behavior,Obesity,and Impaired Glucose Tolerance.Cell Rep 2017;20:136-148[PMID:28683308 DOI:10.1016/j.celrep.2017.06.039]
75 Koeth RA,Wang Z,Levison BS,Buffa JA,Org E,Sheehy BT,Britt EB,Fu X,Wu Y,Li L,Smith JD,DiDonato JA,Chen J,Li H,Wu GD,Lewis JD,Warrier M,Brown JM,Krauss RM,Tang WH,Bushman FD,Lusis AJ,Hazen SL.Intestinal microbiota metabolism of L-carnitine,a nutrient in red meat,promotes atherosclerosis.Nat Med 2013;19:576-585[PMID:23563705 DOI:10.1038/nm.3145]
76 Mehedint MG,Zeisel SH.Choline's role in maintaining liver function:new evidence for epigenetic mechanisms.Curr Opin Clin Nutr Metab Care 2013;16:339-345[PMID:23493015 DOI:10.1097/MCO.0b013e3283600d46]
77 Tang WH,Hazen SL.Microbiome,trimethylamine N-oxide,and cardiometabolic disease.Transl Res2017;179:108-115[PMID:27490453 DOI:10.1016/j.trsl.2016.07.007]
78 Krishnan S,Ding Y,Saedi N,Choi M,Sridharan GV,Sherr DH,Yarmush ML,Alaniz RC,Jayaraman A,Lee K.Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages.Cell Rep 2018;23:1099-1111[PMID:29694888 DOI:10.1016/j.celrep.2018.03.109]
79 Konopelski P,Konop M,Gawrys-Kopczynska M,Podsadni P,Szczepanska A,Ufnal M.Indole-3-Propionic Acid,a Tryptophan-Derived Bacterial Metabolite,Reduces Weight Gain in Rats.Nutrients2019;11[PMID:30862081 DOI:10.3390/nu11030591]
80 Abildgaard A,Elfving B,Hokland M,Wegener G,Lund S.The microbial metabolite indole-3-propionic acid improves glucose metabolism in rats,but does not affect behaviour.Arch Physiol Biochem 2018;124:306-312[PMID:29113509 DOI:10.1080/13813455.2017.1398262]
81 Jennis M,Cavanaugh CR,Leo GC,Mabus JR,Lenhard J,Hornby PJ.Microbiota-derived tryptophan indoles increase after gastric bypass surgery and reduce intestinal permeability in vitro and in vivo.Neurogastroenterol Motil 2018;30[PMID:28782205 DOI:10.1111/nmo.13178]
82 Venkatesh M,Mukherjee S,Wang H,Li H,Sun K,Benechet AP,Qiu Z,Maher L,Redinbo MR,Phillips RS,Fleet JC,Kortagere S,Mukherjee P,Fasano A,Le Ven J,Nicholson JK,Dumas ME,Khanna KM,Mani S.Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4.Immunity 2014;41:296-310[PMID:25065623 DOI:10.1016/j.immuni.2014.06.014]
2 Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLD in Asia.J Hepatol 2017;67:862-873[PMID:28642059 DOI:10.1016/j.jhep.2017.06.003]
3 Day CP,James OF.Steatohepatitis:a tale of two"hits"?Gastroenterology 1998;114:842-845[PMID:9547102]
4 Tilg H,Moschen AR.Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis.Hepatology 2010;52:1836-1846[PMID:21038418 DOI:10.1002/hep.24001]
5 Diehl AM,Day C.Cause,Pathogenesis,and Treatment of Nonalcoholic Steatohepatitis.N Engl J Med2017;377:2063-2072[PMID:29166236 DOI:10.1056/NEJMra1503519]
6 Le Roy T,Llopis M,Lepage P,Bruneau A,Rabot S,Bevilacqua C,Martin P,Philippe C,Walker F,Bado A,Perlemuter G,Cassard-Doulcier AM,Gérard P.Intestinal microbiota determines development of nonalcoholic fatty liver disease in mice.Gut 2013;62:1787-1794[PMID:23197411 DOI:10.1136/gutjnl-2012-303816]
7 Khan R,Bril F,Cusi K,Newsome PN.Modulation of Insulin Resistance in NAFLD.Hepatology 2018[PMID:30556145 DOI:10.1002/hep.30429]
8 Blaut M.Gut microbiota and energy balance:role in obesity.Proc Nutr Soc 2015;74:227-234[PMID:25518735 DOI:10.1017/S0029665114001700]
9 Shen F,Zheng RD,Sun XQ,Ding WJ,Wang XY,Fan JG.Gut microbiota dysbiosis in patients with nonalcoholic fatty liver disease.Hepatobiliary Pancreat Dis Int 2017;16:375-381[PMID:28823367 DOI:10.1016/S1499-3872(17)60019-5]
10 Cao Y,Pan Q,Cai W,Shen F,Chen GY,Xu LM,Fan JG.Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.Arch Iran Med 2016;19:197-203[PMID:26923892 DOI:10.1002/hep.29892]
11 Chu H,Duan Y,Yang L,Schnabl B.Small metabolites,possible big changes:a microbiota-centered view of non-alcoholic fatty liver disease.Gut 2019;68:359-370[PMID:30171065 DOI:10.1136/gutjnl-2018-316307]
12 Caussy C,Hsu C,Lo MT,Liu A,Bettencourt R,Ajmera VH,Bassirian S,Hooker J,Sy E,Richards L,Schork N,Schnabl B,Brenner DA,Sirlin CB,Chen CH,Loomba R;Genetics of NAFLD in Twins Consortium.Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.Hepatology 2018[PMID:29572891 DOI:10.1002/hep.29892]
13 Del Chierico F,Nobili V,Vernocchi P,Russo A,Stefanis C,Gnani D,Furlanello C,ZandonàA,Paci P,Capuani G,Dallapiccola B,Miccheli A,Alisi A,Putignani L.Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.Hepatology 2017;65:451-464[PMID:27028797 DOI:10.1002/hep.28572]
14 Loomba R,Seguritan V,Li W,Long T,Klitgord N,Bhatt A,Dulai PS,Caussy C,Bettencourt R,Highlander SK,Jones MB,Sirlin CB,Schnabl B,Brinkac L,Schork N,Chen CH,Brenner DA,Biggs W,Yooseph S,Venter JC,Nelson KE.Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.Cell Metab 2017;25:1054-1062.e5[PMID:28467925 DOI:10.1016/j.cmet.2017.04.001]
15 Boursier J,Mueller O,Barret M,Machado M,Fizanne L,Araujo-Perez F,Guy CD,Seed PC,Rawls JF,David LA,Hunault G,Oberti F,Calès P,Diehl AM.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.Hepatology 2016;63:764-775[PMID:26600078 DOI:10.1002/hep.28356]
16 Hoyles L,Fernández-Real JM,Federici M,Serino M,Abbott J,Charpentier J,Heymes C,Luque JL,Anthony E,Barton RH,Chilloux J,Myridakis A,Martinez-Gili L,Moreno-Navarrete JM,Benhamed F,Azalbert V,Blasco-Baque V,Puig J,Xifra G,Ricart W,Tomlinson C,Woodbridge M,Cardellini M,Davato F,Cardolini I,Porzio O,Gentileschi P,Lopez F,Foufelle F,Butcher SA,Holmes E,Nicholson JK,Postic C,Burcelin R,Dumas ME.Molecular phenomics and metagenomics of hepatic steatosis in nondiabetic obese women.Nat Med 2018;24:1070-1080[PMID:29942096 DOI:10.1038/s41591-018-0061-3]
17 Panasevich MR,Peppler WT,Oerther DB,Wright DC,Rector RS.Microbiome and NAFLD:potential influence of aerobic fitness and lifestyle modification.Physiol Genomics 2017;49:385-399[PMID:28600319 DOI:10.1152/physiolgenomics.00012.2017]
18 Canfora EE,Meex RCR,Venema K,Blaak EE.Gut microbial metabolites in obesity,NAFLD and T2DM.Nat Rev Endocrinol 2019[PMID:30670819 DOI:10.1038/s41574-019-0156-z]
19 Chambers ES,Viardot A,Psichas A,Morrison DJ,Murphy KG,Zac-Varghese SE,MacDougall K,Preston T,Tedford C,Finlayson GS,Blundell JE,Bell JD,Thomas EL,Mt-Isa S,Ashby D,Gibson GR,Kolida S,Dhillo WS,Bloom SR,Morley W,Clegg S,Frost G.Effects of targeted delivery of propionate to the human colon on appetite regulation,body weight maintenance and adiposity in overweight adults.Gut2015;64:1744-1754[PMID:25500202 DOI:10.1136/gutjnl-2014-307913]
20 Schwiertz A,Taras D,Sch?fer K,Beijer S,Bos NA,Donus C,Hardt PD.Microbiota and SCFA in lean and overweight healthy subjects.Obesity(Silver Spring)2010;18:190-195[PMID:19498350 DOI:10.1038/oby.2009.167]
21 Zhou D,Pan Q,Liu XL,Yang RX,Chen YW,Liu C,Fan JG.Clostridium butyricum B1 alleviates highfat diet-induced steatohepatitis in mice via enterohepatic immunoregulation.J Gastroenterol Hepatol2017;32:1640-1648[PMID:28109017 DOI:10.1111/jgh.13742]
22 Liang Y,Lin C,Zhang Y,Deng Y,Liu C,Yang Q.Probiotic mixture of Lactobacillus and Bifidobacterium alleviates systemic adiposity and inflammation in non-alcoholic fatty liver disease rats through Gpr109a and the commensal metabolite butyrate.Inflammopharmacology 2018;26:1051-1055[PMID:29633106 DOI:10.1007/s10787-018-0479-8]
23 Zhou D,Pan Q,Shen F,Cao HX,Ding WJ,Chen YW,Fan JG.Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota.Sci Rep2017;7:1529[PMID:28484247 DOI:10.1038/s41598-017-01751-y]
24 Zhao L,Zhang F,Ding X,Wu G,Lam YY,Wang X,Fu H,Xue X,Lu C,Ma J,Yu L,Xu C,Ren Z,Xu Y,Xu S,Shen H,Zhu X,Shi Y,Shen Q,Dong W,Liu R,Ling Y,Zeng Y,Wang X,Zhang Q,Wang J,Wang L,Wu Y,Zeng B,Wei H,Zhang M,Peng Y,Zhang C.Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes.Science 2018;359:1151-1156[PMID:29590046 DOI:10.1126/science.aao5774]
25 Bjursell M,Admyre T,G?ransson M,Marley AE,Smith DM,Oscarsson J,Bohlooly-Y M.Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet.Am J Physiol Endocrinol Metab 2011;300:E211-E220[PMID:20959533 DOI:10.1152/ajpendo.00229.2010]
26 Samuel BS,Shaito A,Motoike T,Rey FE,Backhed F,Manchester JK,Hammer RE,Williams SC,Crowley J,Yanagisawa M,Gordon JI.Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor,Gpr41.Proc Natl Acad Sci USA 2008;105:16767-16772[PMID:18931303 DOI:10.1073/pnas.0808567105]
27 Kaji I,Karaki S,Kuwahara A.Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release.Digestion 2014;89:31-36[PMID:24458110 DOI:10.1159/000356211]
28 Schilderink R,Verseijden C,de Jonge WJ.Dietary inhibitors of histone deacetylases in intestinal immunity and homeostasis.Front Immunol 2013;4:226[PMID:23914191 DOI:10.3389/fimmu.2013.00226]
29 Zhou D,Pan Q,Xin FZ,Zhang RN,He CX,Chen GY,Liu C,Chen YW,Fan JG.Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.World J Gastroenterol 2017;23:60-75[PMID:28104981 DOI:10.3748/wjg.v23.i1.60]
30 Zhou D,Chen YW,Zhao ZH,Yang RX,Xin FZ,Liu XL,Pan Q,Zhou H,Fan JG.Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1Rexpression.Exp Mol Med 2018;50:157[PMID:30510243 DOI:10.1038/s12276-018-0183-1]
31 Singh V,Yeoh BS,Chassaing B,Xiao X,Saha P,Aguilera Olvera R,Lapek JD,Zhang L,Wang WB,Hao S,Flythe MD,Gonzalez DJ,Cani PD,Conejo-Garcia JR,Xiong N,Kennett MJ,Joe B,Patterson AD,Gewirtz AT,Vijay-Kumar M.Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer.Cell 2018;175:679-694.e22[PMID:30340040 DOI:10.1016/j.cell.2018.09.004]
32 Cani PD.Microbiota and metabolites in metabolic diseases.Nat Rev Endocrinol 2019;15:69-70[PMID:30602737 DOI:10.1038/s41574-018-0143-9]
33 Fuster D,Samet JH.Alcohol Use in Patients with Chronic Liver Disease.N Engl J Med 2018;379:1251-1261[PMID:30257164 DOI:10.1056/NEJMra1715733]
34 Cope K,Risby T,Diehl AM.Increased gastrointestinal ethanol production in obese mice:implications for fatty liver disease pathogenesis.Gastroenterology 2000;119:1340-1347[PMID:11054393 DOI:10.1053/gast.2000.19267]
35 Zhu L,Baker SS,Gill C,Liu W,Alkhouri R,Baker RD,Gill SR.Characterization of gut microbiomes in nonalcoholic steatohepatitis(NASH)patients:a connection between endogenous alcohol and NASH.Hepatology 2013;57:601-609[PMID:23055155 DOI:10.1002/hep.26093]
36 Michail S,Lin M,Frey MR,Fanter R,Paliy O,Hilbush B,Reo NV.Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease.FEMS Microbiol Ecol 2015;91:1-9[PMID:25764541 DOI:10.1093/femsec/fiu002]
37 Engstler AJ,Aumiller T,Degen C,Dürr M,Weiss E,Maier IB,Schattenberg JM,Jin CJ,Sellmann C,Bergheim I.Insulin resistance alters hepatic ethanol metabolism:studies in mice and children with nonalcoholic fatty liver disease.Gut 2016;65:1564-1571[PMID:26006114 DOI:10.1136/gutjnl-2014-308379]
38 Dornas W,Lagente V.Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis.Pharmacol Res 2019;141:418-428[PMID:30658094 DOI:10.1016/j.phrs.2019.01.026]
39 Sharifnia T,Antoun J,Verriere TG,Suarez G,Wattacheril J,Wilson KT,Peek RM,Abumrad NN,Flynn CR.Hepatic TLR4 signaling in obese NAFLD.Am J Physiol Gastrointest Liver Physiol 2015;309:G270-G278[PMID:26113297 DOI:10.1152/ajpgi.00304.2014]
40 Duparc T,Plovier H,Marrachelli VG,Van Hul M,Essaghir A,St?hlman M,Matamoros S,Geurts L,Pardo-Tendero MM,Druart C,Delzenne NM,Demoulin JB,van der Merwe SW,van Pelt J,B?ckhed F,Monleon D,Everard A,Cani PD.Hepatocyte MyD88 affects bile acids,gut microbiota and metabolome contributing to regulate glucose and lipid metabolism.Gut 2017;66:620-632[PMID:27196572 DOI:10.1136/gutjnl-2015-310904]
41 Kawaratani H,Tsujimoto T,Kitazawa T,Kitade M,Yoshiji H,Uemura M,Fukui H.Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet.World J Gastroenterol2008;14:6655-6661[PMID:19034968 DOI:10.3748/wjg.14.6655]
42 Diether NE,Willing BP.Microbial Fermentation of Dietary Protein:An Important Factor in DietMicrobeHost Interaction.Microorganisms 2019;7[PMID:30642098 DOI:10.3390/microorganisms7010019]
43 Goffredo M,Santoro N,TricòD,Giannini C,D'Adamo E,Zhao H,Peng G,Yu X,Lam TT,Pierpont B,Caprio S,Herzog RI.A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease.Nutrients 2017;9[PMID:28640216 DOI:10.3390/nu9070642]
44 Kaikkonen JE,Würtz P,Suomela E,Lehtovirta M,Kangas AJ,Jula A,Mikkil?V,Viikari JS,Juonala M,R?nnemaa T,Hutri-K?h?nen N,K?h?nen M,Lehtim?ki T,Soininen P,Ala-Korpela M,Raitakari OT.Metabolic profiling of fatty liver in young and middle-aged adults:Cross-sectional and prospective analyses of the Young Finns Study.Hepatology 2017;65:491-500[PMID:27775848 DOI:10.1002/hep.28899]
45 Ottosson F,Brunkwall L,Ericson U,Nilsson PM,Almgren P,Fernandez C,Melander O,Orho-Melander M.Connection Between BMI-Related Plasma Metabolite Profile and Gut Microbiota.J Clin Endocrinol Metab 2018;103:1491-1501[PMID:29409054 DOI:10.1210/jc.2017-02114]
46 Zhang F,Zhao S,Yan W,Xia Y,Chen X,Wang W,Zhang J,Gao C,Peng C,Yan F,Zhao H,Lian K,Lee Y,Zhang L,Lau WB,Ma X,Tao L.Branched Chain Amino Acids Cause Liver Injury in Obese/Diabetic Mice by Promoting Adipocyte Lipolysis and Inhibiting Hepatic Autophagy.EBioMedicine 2016;13:157-167[PMID:27843095 DOI:10.1016/j.ebiom.2016.10.013]
47 Li T,Geng L,Chen X,Miskowiec M,Li X,Dong B.Branched-chain amino acids alleviate nonalcoholic steatohepatitis in rats.Appl Physiol Nutr Metab 2013;38:836-843[PMID:23855271 DOI:10.1139/apnm-2012-0496]
48 Tanaka H,Fukahori S,Baba S,Ueno T,Sivakumar R,Yagi M,Asagiri K,Ishii S,Tanaka Y.BranchedChain Amino Acid-Rich Supplements Containing Microelements Have Antioxidant Effects on Nonalcoholic Steatohepatitis in Mice.JPEN J Parenter Enteral Nutr 2016;40:519-528[PMID:25316683DOI:10.1177/0148607114555160]
49 Honda T,Ishigami M,Luo F,Lingyun M,Ishizu Y,Kuzuya T,Hayashi K,Nakano I,Ishikawa T,Feng GG,Katano Y,Kohama T,Kitaura Y,Shimomura Y,Goto H,Hirooka Y.Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice.Metabolism 2017;69:177-187[PMID:28285648 DOI:10.1016/j.metabol.2016.12.013]
50 Anzai A,Marcondes RR,Gon?alves TH,Carvalho KC,Sim?es MJ,Soares JM Jr,Padmanabhan V,Baracat EC,da Silva IDCG,Maciel GAR.Impaired branched-chain amino acid metabolism may underlie the nonalcoholic fatty liver disease-like pathology of neonatal testosterone-treated female rats.Sci Rep2017;7:13167[PMID:29030588 DOI:10.1038/s41598-017-13451-8]
51 Zhou H,Yu B,Gao J,Htoo JK,Chen D.Regulation of intestinal health by branched-chain amino acids.Anim Sci J 2018;89:3-11[PMID:29164733 DOI:10.1111/asj.12937]
52 Fan JG;Shanghai Multicenter Clinical Cooperative Group of Danning Pian Trial.Evaluating the efficacy and safety of Danning Pian in the short-term treatment of patients with non-alcoholic fatty liver disease:a multicenter clinical trial.Hepatobiliary Pancreat Dis Int 2004;3:375-380[PMID:15313672]
53 Ferslew BC,Xie G,Johnston CK,Su M,Stewart PW,Jia W,Brouwer AS 4th.Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.Dig Dis Sci 2015;60:3318-3328[PMID:26138654 DOI:10.1007/s10620-015-3776-8]
54 Puri P,Daita K,Joyce A,Mirshahi F,Santhekadur PK,Cazanave S,Luketic VA,Siddiqui MS,Boyett S,Min HK,Kumar DP,Kohli R,Zhou H,Hylemon PB,Contos MJ,Idowu M,Sanyal AJ.The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.Hepatology 2017[PMID:28696585 DOI:10.1002/hep.29359]
55 Khandekar MJ,Cohen P,Spiegelman BM.Molecular mechanisms of cancer development in obesity.Nat Rev Cancer 2011;11:886-895[PMID:22113164 DOI:10.1038/nrc3174]
56 Yoshimoto S,Loo TM,Atarashi K,Kanda H,Sato S,Oyadomari S,Iwakura Y,Oshima K,Morita H,Hattori M,Honda K,Ishikawa Y,Hara E,Ohtani N.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.Nature 2013;499:97-101[PMID:23803760 DOI:10.1038/nature12347]
57 Jiao N,Baker SS,Chapa-Rodriguez A,Liu W,Nugent CA,Tsompana M,Mastrandrea L,Buck MJ,Baker RD,Genco RJ,Zhu R,Zhu L.Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.Gut 2018;67:1881-1891[PMID:28774887 DOI:10.1136/gutjnl-2017-314307]
58 Fan JG,Zhong L,Tia LY,Xu ZJ,Li MS,Wang GL.Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.World J Gastroenterol 2005;11:2346-2350[PMID:15818751 DOI:10.3748/wjg.v11.i15.2346]
59 Neuschwander-Tetri BA,Loomba R,Sanyal AJ,Lavine JE,Van Natta ML,Abdelmalek MF,Chalasani N,Dasarathy S,Diehl AM,Hameed B,Kowdley KV,McCullough A,Terrault N,Clark JM,Tonascia J,Brunt EM,Kleiner DE,Doo E;NASH Clinical Research Network.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):a multicentre,randomised,placebo-controlled trial.Lancet 2015;385:956-965[PMID:25468160 DOI:10.1016/S0140-6736(14)61933-4]
60 Arab JP,Karpen SJ,Dawson PA,Arrese M,Trauner M.Bile acids and nonalcoholic fatty liver disease:Molecular insights and therapeutic perspectives.Hepatology 2017;65:350-362[PMID:27358174 DOI:10.1002/hep.28709]
61 Ding L,Sousa KM,Jin L,Dong B,Kim BW,Ramirez R,Xiao Z,Gu Y,Yang Q,Wang J,Yu D,Pigazzi A,Schones D,Yang L,Moore D,Wang Z,Huang W.Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss,improve fatty liver,and remit insulin resistance in mice.Hepatology 2016;64:760-773[PMID:27312543 DOI:10.1002/hep.28689]
62 Guo C,Xie S,Chi Z,Zhang J,Liu Y,Zhang L,Zheng M,Zhang X,Xia D,Ke Y,Lu L,Wang D.Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome.Immunity 2016;45:802-816[PMID:27692610 DOI:10.1016/j.immuni.2016.09.008]
63 Nagahashi M,Takabe K,Liu R,Peng K,Wang X,Wang Y,Hait NC,Wang X,Allegood JC,Yamada A,Aoyagi T,Liang J,Pandak WM,Spiegel S,Hylemon PB,Zhou H.Conjugated bile acid-activated S1Preceptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression.Hepatology 2015;61:1216-1226[PMID:25363242 DOI:10.1002/hep.27592]
64 Smallwood T,Allayee H,Bennett BJ.Choline metabolites:gene by diet interactions.Curr Opin Lipidol2016;27:33-39[PMID:26655287 DOI:10.1097/MOL.0000000000000259]
65 Friedman SL,Neuschwander-Tetri BA,Rinella M,Sanyal AJ.Mechanisms of NAFLD development and therapeutic strategies.Nat Med 2018;24:908-922[PMID:29967350 DOI:10.1038/s41591-018-0104-9]
66 Wang Z,Klipfell E,Bennett BJ,Koeth R,Levison BS,Dugar B,Feldstein AE,Britt EB,Fu X,Chung YM,Wu Y,Schauer P,Smith JD,Allayee H,Tang WH,DiDonato JA,Lusis AJ,Hazen SL.Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.Nature 2011;472:57-63[PMID:21475195 DOI:10.1038/nature09922]
67 Wang Z,Roberts AB,Buffa JA,Levison BS,Zhu W,Org E,Gu X,Huang Y,Zamanian-Daryoush M,Culley MK,DiDonato AJ,Fu X,Hazen JE,Krajcik D,DiDonato JA,Lusis AJ,Hazen SL.Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis.Cell 2015;163:1585-1595[PMID:26687352 DOI:10.1016/j.cell.2015.11.055]
68 Bennett BJ,de Aguiar Vallim TQ,Wang Z,Shih DM,Meng Y,Gregory J,Allayee H,Lee R,Graham M,Crooke R,Edwards PA,Hazen SL,Lusis AJ.Trimethylamine-N-oxide,a metabolite associated with atherosclerosis,exhibits complex genetic and dietary regulation.Cell Metab 2013;17:49-60[PMID:23312283 DOI:10.1016/j.cmet.2012.12.011]
69 Chen YM,Liu Y,Zhou RF,Chen XL,Wang C,Tan XY,Wang LJ,Zheng RD,Zhang HW,Ling WH,Zhu HL.Associations of gut-flora-dependent metabolite trimethylamine-N-oxide,betaine and choline with non-alcoholic fatty liver disease in adults.Sci Rep 2016;6:19076[PMID:26743949 DOI:10.1038/srep19076]
70 Barrea L,Annunziata G,Muscogiuri G,Di Somma C,Laudisio D,Maisto M,de Alteriis G,Tenore GC,Colao A,Savastano S.Trimethylamine-N-oxide(TMAO)as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome.Nutrients 2018;10[PMID:30551613 DOI:10.3390/nu10121971]
71 Dumas ME,Barton RH,Toye A,Cloarec O,Blancher C,Rothwell A,Fearnside J,Tatoud R,Blanc V,Lindon JC,Mitchell SC,Holmes E,McCarthy MI,Scott J,Gauguier D,Nicholson JK.Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.Proc Natl Acad Sci USA 2006;103:12511-12516[PMID:16895997 DOI:10.1073/pnas.0601056103]
72 Gao X,Liu X,Xu J,Xue C,Xue Y,Wang Y.Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet.J Biosci Bioeng 2014;118:476-481[PMID:24721123 DOI:10.1016/j.jbiosc.2014.03.001]
73 Schugar RC,Shih DM,Warrier M,Helsley RN,Burrows A,Ferguson D,Brown AL,Gromovsky AD,Heine M,Chatterjee A,Li L,Li XS,Wang Z,Willard B,Meng Y,Kim H,Che N,Pan C,Lee RG,Crooke RM,Graham MJ,Morton RE,Langefeld CD,Das SK,Rudel LL,Zein N,McCullough AJ,Dasarathy S,Tang WHW,Erokwu BO,Flask CA,Laakso M,Civelek M,Naga Prasad SV,Heeren J,Lusis AJ,Hazen SL,Brown JM.The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue.Cell Rep 2017;19:2451-2461[PMID:28636934 DOI:10.1016/j.celrep.2017.05.077]
74 Dumas ME,Rothwell AR,Hoyles L,Aranias T,Chilloux J,Calderari S,Noll EM,Péan N,BoulangéCL,Blancher C,Barton RH,Gu Q,Fearnside JF,Deshayes C,Hue C,Scott J,Nicholson JK,Gauguier D.Microbial-Host Co-metabolites Are Prodromal Markers Predicting Phenotypic Heterogeneity in Behavior,Obesity,and Impaired Glucose Tolerance.Cell Rep 2017;20:136-148[PMID:28683308 DOI:10.1016/j.celrep.2017.06.039]
75 Koeth RA,Wang Z,Levison BS,Buffa JA,Org E,Sheehy BT,Britt EB,Fu X,Wu Y,Li L,Smith JD,DiDonato JA,Chen J,Li H,Wu GD,Lewis JD,Warrier M,Brown JM,Krauss RM,Tang WH,Bushman FD,Lusis AJ,Hazen SL.Intestinal microbiota metabolism of L-carnitine,a nutrient in red meat,promotes atherosclerosis.Nat Med 2013;19:576-585[PMID:23563705 DOI:10.1038/nm.3145]
76 Mehedint MG,Zeisel SH.Choline's role in maintaining liver function:new evidence for epigenetic mechanisms.Curr Opin Clin Nutr Metab Care 2013;16:339-345[PMID:23493015 DOI:10.1097/MCO.0b013e3283600d46]
77 Tang WH,Hazen SL.Microbiome,trimethylamine N-oxide,and cardiometabolic disease.Transl Res2017;179:108-115[PMID:27490453 DOI:10.1016/j.trsl.2016.07.007]
78 Krishnan S,Ding Y,Saedi N,Choi M,Sridharan GV,Sherr DH,Yarmush ML,Alaniz RC,Jayaraman A,Lee K.Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages.Cell Rep 2018;23:1099-1111[PMID:29694888 DOI:10.1016/j.celrep.2018.03.109]
79 Konopelski P,Konop M,Gawrys-Kopczynska M,Podsadni P,Szczepanska A,Ufnal M.Indole-3-Propionic Acid,a Tryptophan-Derived Bacterial Metabolite,Reduces Weight Gain in Rats.Nutrients2019;11[PMID:30862081 DOI:10.3390/nu11030591]
80 Abildgaard A,Elfving B,Hokland M,Wegener G,Lund S.The microbial metabolite indole-3-propionic acid improves glucose metabolism in rats,but does not affect behaviour.Arch Physiol Biochem 2018;124:306-312[PMID:29113509 DOI:10.1080/13813455.2017.1398262]
81 Jennis M,Cavanaugh CR,Leo GC,Mabus JR,Lenhard J,Hornby PJ.Microbiota-derived tryptophan indoles increase after gastric bypass surgery and reduce intestinal permeability in vitro and in vivo.Neurogastroenterol Motil 2018;30[PMID:28782205 DOI:10.1111/nmo.13178]
82 Venkatesh M,Mukherjee S,Wang H,Li H,Sun K,Benechet AP,Qiu Z,Maher L,Redinbo MR,Phillips RS,Fleet JC,Kortagere S,Mukherjee P,Fasano A,Le Ven J,Nicholson JK,Dumas ME,Khanna KM,Mani S.Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4.Immunity 2014;41:296-310[PMID:25065623 DOI:10.1016/j.immuni.2014.06.014]